Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Alteration of sphingolipid metabolism as a putative mechanism underlying LPS-induced BBB disruption.

Journal of neurochemistry | 2018

Septic encephalopathy with confusion and agitation occurs early during sepsis and contributes to the severity of the disease. A decrease in the sphingosine-1-phosphate (S1P) blood levels has been shown in patients and in animal models of sepsis. The lipid mediator S1P is known to be involved in endothelial barrier function in a context-dependent manner. We utilized lipopolysaccharide (LPS)-injected mice as a model for septic encephalopathy and first performed tracer permeability assays to assess the blood-brain barrier (BBB) breakdown in vivo. At time points corresponding to the BBB breakdown post LPS injection, we aimed to characterize the regulation of the sphingolipid signaling pathway at the BBB during sepsis. We measured sphingolipid concentrations in blood, in mouse brain microvessels (MBMVs), and brain tissue. We also analyzed the expression of S1P receptors, transporters, and metabolizing enzymes in MBMVs and brain tissue. Primary mouse brain microvascular endothelial cells (MBMECs) were isolated to evaluate the effects of LPS on transendothelial electrical resistance (TEER) as a measure of permeability in vitro. We observed a relevant decrease in S1P levels after LPS injection in all three compartments (blood, MBMVs, brain tissue) that was accompanied by an increased expression of the S1P receptor type 1 and of sphingosine kinase 1 on one hand and of the S1P degrading enzymes lipid phosphate phosphatase 1 (LPP1) and S1P phosphatase 1 on the other hand, as well as a down-regulation of sphingosine kinase 2. Application of LPS to a monolayer of primary MBMECs did not alter TEER, but serum from LPS-treated mice lead to a breakdown of the barrier compared to serum from vehicle-treated mice. We observed profound alterations of the sphingolipid metabolism at the BBB after LPS injection that point toward a therapeutic potential of drugs interfering with this pathway as novel approach for the detrimental overwhelming immune response in sepsis. Read the Editorial Highlight for this article on page 115. Cover Image for this Issue: doi. 10.1111/jnc.14161.

Pubmed ID: 29023711 RIS Download

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Anti-Glial Fibrillary Acidic Protein (GFAP) (antibody)

RRID:AB_2109645

This polyclonal targets Glial Fibrillary Acidic Protein (GFAP)

View all literature mentions

beta-Actin (AC-15) (antibody)

RRID:AB_1119529

This monoclonal targets beta-Actin (AC-15)

View all literature mentions

VE-cadherin (C-19) (antibody)

RRID:AB_2077955

This polyclonal targets CDH5

View all literature mentions

SGPP2 (sphingosine-1-phosphate phosphotase 2) Antibody (against the C terminal of SGPP2) (100ug) (antibody)

RRID:AB_938387

This polyclonal targets SGPP2 (sphingosine-1-phosphate phosphotase 2) (against the C terminal of SGPP2) (100ug)

View all literature mentions

sphingosine-1-phosphate phosphatase 1 antibody (antibody)

RRID:AB_10889706

This polyclonal targets sphingosine-1-phosphate phosphatase 1 antibody

View all literature mentions

SPHK2 antibody (antibody)

RRID:AB_778046

This polyclonal targets SPHK2 antibody

View all literature mentions

C57BL/6J (organism)

RRID:IMSR_JAX:000664

Mus musculus with name C57BL/6J from IMSR.

View all literature mentions

Anti-Glial Fibrillary Acidic Protein (GFAP) (antibody)

RRID:AB_2109645

This polyclonal targets Glial Fibrillary Acidic Protein (GFAP)

View all literature mentions